Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trialsEdward M Vital, Raj Tummala, Ian N Bruce et al.|Annals of the Rheumatic Diseases|2022Cited by 141
A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunityJodi L. Karnell, Jörn Drappa, M. Albulescu et al.|Science Translational Medicine|2019Cited by 98